logo
logo

Receptor Life Sciences Secures $9.7 Million Financing To Advance Rls103 (Inhaled Dry Powder Cbd) Into Clinical Trials

Apr 07, 2022•over 3 years ago

Amount Raised

$9.7 Million

Seattle

Description

Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, today announced the closing of a $9.7 million Series A-1 financing. The financing was led by Granite Point Capital, with participation from existing Series A and a syndicate of new investors.

Company Information

Company

Receptor Life Sciences

Location

Seattle, Washington, United States

About

Receptor Life Sciences is a pharmaceutical company that applies FDA-approved drug delivery technologies to develop innovative therapies to address central nervous system disorders that have few safe and effective treatments. Receptor Life Sciences uses these technologies to produce inhaled and oral cannabinoid products that hold the potential to provide precision, consistency, reliability, and convenience. For more information about Receptor Life Sciences, its patented product candidates and its progress toward FDA approval, see www.receptorlife.com.